BiotechTube

Alogabat

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angelman Syndrome

Conditions

Angelman Syndrome

Trial Timeline

Jul 27, 2023 → Dec 2, 2025

NCT ID
NCT05630066

About Alogabat

Alogabat is a phase 2 stage product being developed by Roche for Angelman Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05630066. Target conditions include Angelman Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05630066Phase 2Completed

Competing Products

9 competing products in Angelman Syndrome

See all competitors
ProductCompanyStageHype Score
RO7248824RochePhase 1
33
RO7248824RochePhase 1
33
ION582Ionis PharmaceuticalsPhase 1/2
38
ION582 + PlaceboIonis PharmaceuticalsPhase 3
74
GTX-102Ultragenyx PharmaceuticalPhase 3
72
GTX-102Ultragenyx PharmaceuticalPhase 3
72
GTX-102Ultragenyx PharmaceuticalPhase 2
47
GTX-102Ultragenyx PharmaceuticalPhase 1/2
36
NNZ-2591Neuren PharmaceuticalsPhase 2
47

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85